FR88M - - Google Patents

Info

Publication number
FR88M
FR88M FR834523A FR834523A FR88M FR 88 M FR88 M FR 88M FR 834523 A FR834523 A FR 834523A FR 834523 A FR834523 A FR 834523A FR 88 M FR88 M FR 88M
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR834523A
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to FR834523A priority Critical patent/FR88M/fr
Application granted granted Critical
Publication of FR88M publication Critical patent/FR88M/fr
Priority to GB26856/61A priority patent/GB922361A/en
Priority to CH884561A priority patent/CH394216A/fr
Priority to BE606638A priority patent/BE606638A/fr
Priority to US127154A priority patent/US3161565A/en
Priority to ES0269442A priority patent/ES269442A1/es
Priority to DK312061AA priority patent/DK105811C/da
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR834523A 1960-07-29 1960-07-29 Active FR88M (xx)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR834523A FR88M (xx) 1960-07-29 1960-07-29
GB26856/61A GB922361A (en) 1960-07-29 1961-07-25 Improvements in and relating to lysine orotate and its therapeutic applications
CH884561A CH394216A (fr) 1960-07-29 1961-07-27 Procédé de préparation d'orotate de lysine
BE606638A BE606638A (fr) 1960-07-29 1961-07-27 Orotate de lysine et ses applications thérapeutiques
US127154A US3161565A (en) 1960-07-29 1961-07-27 Lysine orotate
ES0269442A ES269442A1 (es) 1960-07-29 1961-07-28 Procedimiento de preparaciën de orotato de lisina
DK312061AA DK105811C (da) 1960-07-29 1961-07-28 Fremgangsmåde til fremstilling af lysinorotat.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR834523A FR88M (xx) 1960-07-29 1960-07-29

Publications (1)

Publication Number Publication Date
FR88M true FR88M (xx) 1961-01-09

Family

ID=8736588

Family Applications (1)

Application Number Title Priority Date Filing Date
FR834523A Active FR88M (xx) 1960-07-29 1960-07-29

Country Status (7)

Country Link
US (1) US3161565A (xx)
BE (1) BE606638A (xx)
CH (1) CH394216A (xx)
DK (1) DK105811C (xx)
ES (1) ES269442A1 (xx)
FR (1) FR88M (xx)
GB (1) GB922361A (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037488A2 (de) * 1980-03-25 1981-10-14 Hrvoje Dr. Krnjevic Pharmazeutisches Mittel zur Heilung von entzündlichen und/oder degenerativen und/oder atrophischen Schleimhauterkrankungen

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US7776838B1 (en) 1987-10-28 2010-08-17 Wellstat Therapeutics Corporation Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US7173017B1 (en) * 1987-10-28 2007-02-06 Wellstat Therapeutics Corporation Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
AU712679B2 (en) * 1994-07-01 1999-11-11 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2556907A (en) * 1950-01-27 1951-06-12 Du Pont Resolution of lysine
US2738299A (en) * 1953-05-11 1956-03-13 Abbott Lab Stable nutritive amino acid compositions
US2802864A (en) * 1953-09-01 1957-08-13 Int Minerals & Chem Corp Higher alkyl amine salts of glutamic acid
US2992163A (en) * 1955-11-07 1961-07-11 Lilly Co Eli Use of 4-chloro-1, 2-pyrazole for controlling epileptic seizures
US2859244A (en) * 1956-09-28 1958-11-04 Dow Chemical Co Resolution of dl-lysine with d-camphoric acid
US3020278A (en) * 1959-09-16 1962-02-06 Jr Edgar A Ferguson Vitamin-orotic acid compositions
US3062722A (en) * 1960-03-15 1962-11-06 Garofalo Domenico Therapeutic 2-aminoethanethiol orate

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037488A2 (de) * 1980-03-25 1981-10-14 Hrvoje Dr. Krnjevic Pharmazeutisches Mittel zur Heilung von entzündlichen und/oder degenerativen und/oder atrophischen Schleimhauterkrankungen
EP0037488A3 (en) * 1980-03-25 1982-11-24 Hrvoje Dr. Krnjevic Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes

Also Published As

Publication number Publication date
GB922361A (en) 1963-03-27
DK105811C (da) 1966-11-14
US3161565A (en) 1964-12-15
BE606638A (fr) 1961-11-16
CH394216A (fr) 1965-06-30
ES269442A1 (es) 1962-01-01

Similar Documents

Publication Publication Date Title
FR1310106A (xx)
BE609442A (xx)
FI40967B (xx)
FR707M (xx)
DE1287959B (xx)
FR907M (xx)
FI41260B (xx)
FR1563606A (xx)
FI44990B (xx)
FR674M (xx)
FI40547B (xx)
FR602M (xx)
DE1608578A1 (xx)
DE1423743B2 (xx)
BE611639A (xx)
BE605775A (xx)
NL122197C (xx)
BE599030A (xx)
BE609410A (xx)
BE600332A (xx)
BE605287A (xx)
BE608384A (xx)
BE607203A (xx)
BE611208A (xx)
LU40997A1 (xx)